AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22507468 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% liposomal lidocaine gel (LMX4 gel)
Number of subjects: 15
Study 22507468 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream (2.5% lidocaine and 2.5% prilocaine) applied for 30 min
Number of subjects: 15
Study 22507468 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream (2.5% lidocaine and 2.5% prilocaine) applied for 60 min
Number of subjects: 15
Study 20678674 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination treatment with OM 40 mg + AML 10 mg + HCTZ 25 mg
Number of subjects: 2492
Study 20678674 — intervention group
Group type: COMPARATOR
Intervention: Dual combinations (OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, AML 10 mg + HCTZ 25 mg)
Number of subjects: 2492
Study 20678674 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination treatment
Number of subjects: 2492
Study 20678674 — intervention group
Group type: COMPARATOR
Intervention: Dual combinations
Number of subjects: 2492
Study 20678674 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 2492
Study 17877520 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic diary
Number of subjects: 36
Study 17877520 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 36
Study 15722295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen patch (100 mg) applied once a day for 7 days
Number of subjects: 163
Study 15722295 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch applied once a day for 7 days
Number of subjects: 163
Study 12230150 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. children
Number of subjects: 202
Study 12230150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both countries
Number of subjects: 202
Study 10434823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA) as an adjunct to fibreoptic tracheal intubation
Number of subjects: 40
Study 7577027 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusions
Number of subjects: 0
Study 7577027 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusions
Number of subjects: 0
Study 7577027 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfused patients
Number of subjects: 0
Study 7577027 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 0
Study 7577027 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions
Number of subjects: 0
Study 2182407 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (alpha-IFN, 10(6) IU in a 3.5% aqueous methylcellulose base) without 1% nonoxynol-9 (−N)
Number of subjects: 21
Study 2182407 — intervention group
Group type: COMPARATOR
Intervention: alpha-interferon (alpha-IFN, 10(6) IU in a 3.5% aqueous methylcellulose base) with 1% nonoxynol-9 (+N)
Number of subjects: 21
Study 6260126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole suppositories
Number of subjects: 192
Study 31156170 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with memantine
Number of subjects: 0
Study 31156170 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a nursing home/care facility
Number of subjects: 0
Study 31156170 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dementia
Number of subjects: 0
Study 31156170 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild dementia
Number of subjects: 0
Study 31156170 — intervention group
Group type: EXPERIMENTAL
Intervention: At least five comorbidities
Number of subjects: 0
Study 31156170 — intervention group
Group type: EXPERIMENTAL
Intervention: No comorbidities
Number of subjects: 0
Study 28742713 — intervention group
Group type: EXPERIMENTAL
Intervention: EN-EPA (2.2 g EPA/day)
Number of subjects: 191
Study 28742713 — intervention group
Group type: COMPARATOR
Intervention: EN-S (isocaloric isonitrogenous standard EN)
Number of subjects: 191
Study 28742713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 191
Study 26346765 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniplate only (Group A)
Number of subjects: 25
Study 26346765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined with single bicortical screw (Group B)
Number of subjects: 25
Study 26346765 — intervention group
Group type: EXPERIMENTAL
Intervention: With more than one bicortical screw (Group C)
Number of subjects: 25
Study 23426700 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID
Number of subjects: 57
Study 23426700 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular corticosteroid injection
Number of subjects: 57
Study 21750726 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated presentations of four types of complex visual scenes in a pseudo-randomized order.
Number of subjects: 0
Study 21750726 — intervention group
Group type: COMPARATOR
Intervention: Group of subjects who rated the image set as interesting.
Number of subjects: 0
Study 21750726 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects' motivational disposition.
Number of subjects: 0
Study 21750726 — intervention group
Group type: EXPERIMENTAL
Intervention: Image type.
Number of subjects: 0
Study 19317200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative sock systems
Number of subjects: 173
Study 19317200 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 173
Study 17027429 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point frequency format
Number of subjects: 0
Study 17027429 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point intensity format
Number of subjects: 0
Study 17027429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-point similarity format
Number of subjects: 0
Study 17027429 — intervention group
Group type: COMPARATOR
Intervention: Original 'yes/no' format
Number of subjects: 0
Study 17027429 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point formats (intensity and frequency)
Number of subjects: 0
Study 12719078 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily in the evening
Number of subjects: 410
Study 12719078 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost 0.03% once daily in the evening
Number of subjects: 410
Study 12719078 — intervention group
Group type: COMPARATOR
Intervention: Travoprost 0.004% once daily in the evening
Number of subjects: 410
Study 10852765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GSH 70 mg/kg/d
Number of subjects: 30
Study 10852765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GSH 70 mg/kg/d and intravenous NAC 75 mg/kg/d
Number of subjects: 30
Study 10852765 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard septic shock therapy only)
Number of subjects: 30
Study 9489193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-out of a sample sun-protection policy kit
Number of subjects: 781
Study 9489193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-out of the policy kit and a follow-up mail-out of a staff development module
Number of subjects: 781
Study 8258959 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (ethyl esters, EPA+DHA = 7.7 g/day)
Number of subjects: 14
Study 4042390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 19
Study 4042390 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets twice daily
Number of subjects: 19
Study 31522699 — intervention group
Group type: EXPERIMENTAL
Intervention: Harti Hauora Tamariki tool (Harti tool)
Number of subjects: 0
Study 30009733 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation physiotherapy (including limb active/passive activities, respiratory muscle function training, and transcutaneous electrical nerve stimulation)
Number of subjects: 40
Study 30009733 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation physiotherapy
Number of subjects: 40
Study 30009733 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 40
Study 27509605 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at stellate ganglion combined with intravenous administration of alprostadil (10 µg) and sodium chloride solution (100 mL)
Number of subjects: 60
Study 27509605 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of alprostadil (10 µg) and sodium chloride solution (100 mL)
Number of subjects: 60
Study 25225285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg bid for 24 weeks (Group A)
Number of subjects: 323
Study 25225285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg bid for 4 weeks, then 150 mg qd (Group B)
Number of subjects: 323
Study 25225285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 323
Study 23207783 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean hand acupuncture (KHA)
Number of subjects: 42
Study 23207783 — intervention group
Group type: COMPARATOR
Intervention: Sham KHA
Number of subjects: 42
Study 19968158 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed haemorrhoidectomy
Number of subjects: 56
Study 19968158 — intervention group
Group type: COMPARATOR
Intervention: Open haemorrhoidectomy
Number of subjects: 56
Study 17727588 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with music (12 weeks)
Number of subjects: 365
Study 15014210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial prevention and termination therapies ON (n = 199)
Number of subjects: 451
Study 15014210 — intervention group
Group type: COMPARATOR
Intervention: Atrial prevention and termination therapies OFF (n = 206)
Number of subjects: 451
Study 15014210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial prevention and termination therapies ON (subgroup of 192 patients with a history of ATA's)
Number of subjects: 451
Study 15014210 — intervention group
Group type: COMPARATOR
Intervention: Atrial prevention and termination therapies OFF (subgroup of 192 patients with a history of ATA's)
Number of subjects: 451
Study 12503233 — intervention group
Group type: EXPERIMENTAL
Intervention: SC's nutrition program
Number of subjects: 238
Study 12503233 — intervention group
Group type: COMPARATOR
Intervention: Comparison children
Number of subjects: 238
Study 9834044 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 9834044 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0
Study 9834044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9834044 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 9834044 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study 8077888 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 36
Study 2589002 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 2589002 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 60
Study 2589002 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 60
Study 815188 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol plus codeine (P + C) 350 + 20 mg
Number of subjects: 47
Study 815188 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 500 mg
Number of subjects: 47
Study 815188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30862526 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-periodized resistance training (NP)
Number of subjects: 42
Study 30862526 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily undulating periodization resistance training (DUP)
Number of subjects: 42
Study 30862526 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study 29162132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level MAP (90-100 mmHg)
Number of subjects: 322
Study 29162132 — intervention group
Group type: COMPARATOR
Intervention: Low-level MAP (60-70 mmHg)
Number of subjects: 322
Study 25415247 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination 70% mineralized: 30% demineralized FDBA
Number of subjects: 42
Study 25415247 — intervention group
Group type: COMPARATOR
Intervention: 100% mineralized FDBA
Number of subjects: 42
Study 23489754 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline pleurodesis (300 mg)
Number of subjects: 214
Study 23489754 — intervention group
Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 214
Study 21619621 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-serve evidence service (database access, monthly e-mail alerts, and full-text article availability)
Number of subjects: 168
Study 21619621 — intervention group
Group type: COMPARATOR
Intervention: Self-serve evidence service (database access only)
Number of subjects: 168
Study 18028181 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control strategy
Number of subjects: 0
Study 18028181 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control strategy
Number of subjects: 0
Study 18028181 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment initiation
Number of subjects: 0
Study 18028181 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockers of the renin angiotensin system and statins
Number of subjects: 0
Study 18028181 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 0
Study 18028181 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial specific antiarrhythmic drugs and direct thrombin inhibitors
Number of subjects: 0
Study 15800330 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home‐based flexible training program (14 weeks)
Number of subjects: 111
Study 15800330 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 111
Study 12354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of long-term antipsychotic medication
Number of subjects: 0
Study 12354317 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9872197 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol treatment (n=8)
Number of subjects: 238
Study 9872197 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=7)
Number of subjects: 238
Study 9872197 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of EIB in athletes
Number of subjects: 238
Study 9872197 — intervention group
Group type: EXPERIMENTAL
Intervention: EIB prevalence by race
Number of subjects: 238
Study 9872197 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic associations with EIB
Number of subjects: 238
Study 7625335 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion Recovery (IR) method
Number of subjects: 158
Study 7625335 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin Echo method
Number of subjects: 158
Study 7625335 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IR and Spin Echo
Number of subjects: 158
Study 2750674 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin (12,500 U subcutaneously every 12 hours for 10 days)
Number of subjects: 100
Study 2750674 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin (5,000 U subcutaneously every 12 hours for 10 days)
Number of subjects: 100
Study 319692 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine; specific dosage and duration not mentioned
Number of subjects: 0
Study 319692 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal children); specific details not mentioned
Number of subjects: 0
Study 31899035 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated neovascular age‐related macular degeneration (nAMD)
Number of subjects: 627
Study 31899035 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic atrophy (GA) in the fellow eye
Number of subjects: 627
Study 31899035 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 52‐single nucleotide polymorphism AMD genetic risk score
Number of subjects: 627
Study 31899035 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs at CFH, ARMS2, or C3
Number of subjects: 627
Study 31255449 — intervention group
Group type: EXPERIMENTAL
Intervention: AeRop exercise
Number of subjects: 64
Study 31255449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AeRop exercise)
Number of subjects: 64
Study 27995939 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based management (weekly advice by telephone for 12 weeks)
Number of subjects: 120
Study 27995939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 27995939 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based management
Number of subjects: 120
Study 25819700 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (starting dose of 6.25mg, followed by long-acting injectable naltrexone)
Number of subjects: 6
Study 24355949 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Lippia sidoides (LS)
Number of subjects: 10
Study 24355949 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine digluconate
Number of subjects: 10
Study 24355949 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (negative control)
Number of subjects: 10
Study 22000810 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab 6 mg/kg + FOLFIRI every 2 weeks
Number of subjects: 95
Study 22000810 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab 9 mg/kg + irinotecan every 3 weeks
Number of subjects: 95
Study 22000810 — intervention group
Group type: COMPARATOR
Intervention: Panitumumab (both dosages)
Number of subjects: 95
Study 17628656 — intervention group
Group type: EXPERIMENTAL
Intervention: Right visual field presentation of stimuli
Number of subjects: 0
Study 17628656 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased demands on verbal working memory via a secondary task
Number of subjects: 0
Study 17628656 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased demands on spatial working memory via a secondary task
Number of subjects: 0
Study 16563893 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to normal activities at 2 weeks after AMI
Number of subjects: 142
Study 16563893 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation and return to normal activities at 6 weeks after AMI
Number of subjects: 142
Study 15145000 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetry Aortic Connector (Group I, n = 39)
Number of subjects: 77
Study 15145000 — intervention group
Group type: COMPARATOR
Intervention: Conventional handsewn anastomosis (Group II, n = 38)
Number of subjects: 77
Study 12397461 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAC (scatter correction and attenuation correction)
Number of subjects: 142
Study 12397461 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected images
Number of subjects: 142
Study 12397461 — intervention group
Group type: COMPARATOR
Intervention: CAG (coronary angiography)
Number of subjects: 142
Study 9617707 — intervention group
Group type: EXPERIMENTAL
Intervention: Good repositioning quality
Number of subjects: 9
Study 9617707 — intervention group
Group type: COMPARATOR
Intervention: Poor repositioning quality
Number of subjects: 9
Study 9617707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer variability
Number of subjects: 9
Study 7659631 — intervention group
Group type: EXPERIMENTAL
Intervention: Content plus instruction on their own breasts
Number of subjects: 614
Study 7659631 — intervention group
Group type: COMPARATOR
Intervention: Content plus supervised practice on a model with implanted lumps
Number of subjects: 614
Study 7659631 — intervention group
Group type: COMPARATOR
Intervention: Content only
Number of subjects: 614
Study 2714088 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel (synthetic polyvinyl sponge with magnesium sulphate)
Number of subjects: 41
Study 2714088 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic tent without magnesium sulphate
Number of subjects: 41
Study 2714088 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 patients)
Number of subjects: 41
Study 328243 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 58
Study 328243 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 58
Study 328243 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 58
Study 31099387 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan + Amlodipine (L/A)
Number of subjects: 231
Study 31099387 — intervention group
Group type: COMPARATOR
Intervention: Losartan + Hydrochlorothiazide (L/H)
Number of subjects: 231
Study 27869476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to maxillary incisors with a dose of 2 J/point, starting immediately after archwire insertion and repeated on specific days until the end of the leveling and alignment stage.
Number of subjects: 26
Study 27869476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT treatment).
Number of subjects: 26
Study 25814264 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach intervention
Number of subjects: 420
Study 25814264 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 420
Study 23519634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (SUG group, n=20)
Number of subjects: 40
Study 23519634 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine plus atropine (NEO group, n=20)
Number of subjects: 40
Study 21725872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines
Number of subjects: 300000000
Study 19135563 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 480
Study 19135563 — intervention group
Group type: COMPARATOR
Intervention: 400 mcg oral misoprostol
Number of subjects: 480
Study 19135563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sublingual and oral misoprostol
Number of subjects: 480
Study 19135563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 480
Study 17306999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed mode delivery
Number of subjects: 138
Study 17306999 — intervention group
Group type: COMPARATOR
Intervention: Near-continuous mode delivery
Number of subjects: 138
Study 17306999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138